MedTrace Logo

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

NCT05708573 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-14

No results posted yet for this study

Summary

This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.

Conditions

  • Healthy Participants

Interventions

DRUG

Rosuvastatin

In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).

DRUG

ALXN2040

In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2023-03-23
Completion
2023-04-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05708573 on ClinicalTrials.gov